GlassScriptPhysician profile
Michael J Maloney
NPI 1912901844
$7,237.98
in general payments reported to CMS, 2019-2025
29 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2020: $656 · 2021: $1,051 · 2022: $747 · 2023: $1,143 · 2024: $980 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,552 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,551.78 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,510.26 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,185.16 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $868.29 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $501.69 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $361.16 | 2022-2025 | Tezspire |
| Pfizer INC. | $290.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $249.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.87 | 2019-2023 | Spiriva Respimat |
| Octapharma USA, INC. | $241.36 | 2020-2021 | |
| Pharming Healthcare, INC. | $177.97 | 2023-2025 | Ruconest |
| Covis Pharma Gmbh | $162.67 | 2021-2022 | |
| Grifols USA, LLC | $160.04 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $159.16 | 2019-2025 | Hizentra, Haegarda |
| Alk-Abello, INC | $132.36 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Takeda Pharmaceuticals U.S.A., INC. | $132.21 | 2021-2025 | Cuvitru, Takhzyro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $125.91 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $121.40 | 2021-2025 | Orladeyo |
| Abbvie INC. | $108.49 | 2022-2024 | |
| Galderma Laboratories, L.P. | $90.96 | 2025 | Nemluvio |
| Kaleo, INC. | $81.65 | 2019-2022 | |
| Incyte Corporation | $73.49 | 2021-2022 | |
| Leo Pharma INC. | $70.44 | 2022-2023 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $59.78 | 2025 | Neffy |
| Aytu Biopharma, INC. | $33.57 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $31.53 | 2019-2021 | |
| Shire North American Group INC | $28.83 | 2019 | |
| Aimmune Therapeutics, INC. | $19.08 | 2021 | |
| Uswm, LLC | $15.00 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maloney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.